Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Phase 2

Completed

• Conditions: Tetanus; Diphtheria; Poliomyelitis; Acellular Pertussis; Hepatitis B; Haemophilus Influenzae Type b
• Interventions: Biological: Infanrix hexa; Biological: Prevenar 13; Biological: GSK217744

• Registration Number: NCT01453998
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the booster vaccine dose of 2 new formulations of DTPa-HBV-IPV/Hib administered between 12 and 15 months of age, and the immune persistence following the primary series. All children in this booster study received a primary vaccination at 2, 3 and 4 months of age in study 113948 (NCT01248884). No new subjects will be enrolled in this booster study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-10-06
• Study Start: 2011-10-14
• Study First Submitted QC: 2011-10-14
• Study First Posted: 2011-10-18
• Primary Completion: 2012-11-12
• Study Completion: 2012-11-12
• Disposition First Submitted: 2012-11-16
• Disposition First Submitted QC: 2012-11-16
• Disposition First Posted: 2012-11-21
• Results First Submitted: 2014-05-01
• Results First Submitted QC: 2014-07-24
• Results First Posted: 2014-07-28
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-03
• Last Update Posted: 2020-07-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 657

Inclusion Criteria

• Subjects who participated in the study 113948 (NCT01248884) and received three doses of the new or licensed DTPa-HBV-IPV/Hib study vaccine.
• A male or female child between, and including, 12 and 15 months of age at the time of the booster vaccination.
• Subjects who the investigator believes that parent(s)/ Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visit).
• Written informed consent obtained from the parent(s)/LAR(s) of the subject.
• Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria

• Child in care.

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the booster dose of study vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.

• Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period.

• Participation in another clinical study within three months prior to enrolment in the present booster study or at any time during the present booster study, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

• Evidence of previous or intercurrent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Hib vaccination or disease since the conclusion visit of study 113948 (NCT01248884).

• Serious chronic illness.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).

• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.

• History of any neurological disorders or seizures.

• Administration of immunoglobulins and/or any blood products within the 3 months preceding the booster dose of study vaccine or planned administration during the study period.

• Occurrence of any of the following events following previous administration of the study vaccine constitutes an absolute contraindication to further dosing.

  • Anaphylactic or other hypersensitivity reaction.
  • Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours.
  • Temperature of ≥ 40.0°C (axillary) or 40.5°C (rectal) within 48 hours of vaccination, not due to another identifiable cause.
  • Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
  • Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
  • Seizures with or without fever occurring within 3 days of vaccination.

The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:

• Acute disease and/or fever at the time of enrolment.

• Fever is defined as temperature ≥ 37.5°C on oral, axillary or tympanic setting, or ≥ 38.0° on rectal setting.
• Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
GSK217744 Group 2	Prevenar 13	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
GSK217744 Group 1	Infanrix hexa	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
GSK217744 Group 2	Infanrix hexa	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
GSK217744 Group 1	Prevenar 13	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
GSK217744 Group 1	GSK217744	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
GSK217744 Group 2	GSK217744	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
Infanrix hexa Group	Prevenar 13	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
Infanrix hexa Group	Infanrix hexa	Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.

Primary Outcome Measures

Name	Time	Method
Number of Seroprotected Subjects for Anti-poliovirus Type 1, 2 and 3	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	A seroprotected subject was a subject whose antibody titre was greater than or equal to the level defining clinical protection of 8.
Number of Seroprotected Subjects Against Anti-HBs Antigens	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	A seroprotected subject was a subject whose antibody concentration was greater than or equal to the level defining clinical protection of 10 milli-international units per millilitre (mIU/mL).
Number of Seroprotected Subjects for Anti-polyribosyl-ribitol Phosphate (Anti-PRP)	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL).
Number of Seroprotected Subjects Against Anti-Hepatitis B (Anti-HBs) Antigens	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	A seroprotected subject was a subject whose antibody concentration was greater than or equal to the level defining clinical protection of 10 milli-international units per millilitre (mIU/mL).
Number of Seroprotected Subjects for Anti-poliovirus Types 1, 2 and 3	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	A seroprotected subject was a subject whose antibody titre was greater than or equal to the level defining clinical protection of 8.
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Number of Seroprotected Subjects for Anti-D and Anti-T Antibodies	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Number of Seroprotected Subjects for Anti-PRP	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL).
Concentrations for Anti-Pertussis Toxoid (Anti-PT), Anti-Filamentous Haemagglutinin (Anti-FHA), Anti-Pertactin (Anti-PRN)	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). Seropositivity cut-off assay was 5 EL.U/mL.
Concentrations for Anti-PT, Anti-FHA and Anti-PRN	1 month post booster vaccination (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). Seropositivity cut-off assay was 5 EL.U/mL.

Secondary Outcome Measures

Name	Time	Method
Number of Seroprotected Subjects for Anti-D and Anti-T Antibodies	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Number of Seropositive Subjects for Anti-Pertussis Toxoid (Anti-PT), Anti-Filamentous Haemagglutinin (Anti-FHA), Anti-Pertactin (Anti-PRN)	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the assay cut-off of 5 ELISA units per milliliter (EL.U/mL).
Concentrations for Anti-poliovirus Types 1, 2, 3	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean titers (GMTs). The seroprotection cut-off of the assay was 8.
Number of Seroprotected Subjects for Anti-poliovirus Type 1, 2 and 3	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	A seroprotected subject was a subject whose antibody titre was greater than or equal to the level defining clinical protection of 8.
Concentrations for Anti-Pertussis Toxoid (Anti-PT), Anti-Filamentous Haemagglutinin (Anti-FHA), Anti-Pertactin (Anti-PRN)	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). Seropositivity cut-off assay was 5 EL.U/mL.
Number of Seropositive Subjects for Anti-PT, Anti-FHA, Anti-PRN	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)	A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the assay cut-off of 5 ELISA units per milliliter (EL.U/mL).
Concentration for Anti-poliovirus Types 1, 2, 3	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean titers (GMTs). The seroprotection cut-off of the assay was 8.
Number of Seropositive Subjects for Anti-pneumococcal (Anti-PNE) Serotypes	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	A seropositive subject was defined as a vaccinated subject who had anti- pneumococcal antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL). The anti-PNE serotypes assessed were 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Number of Subjects With Booster Response to Anti-pertussis Antigens (Anti-PT, Anti-FHA and Anti-PRN)	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	Booster response defined as : - For initially seronegative subjects, antibody concentration ≥ 5 EL.U/mL one month after booster vaccination - For initially seropositive subjects, antibody concentration at Post-booster ≥ 2 fold the pre-vaccination antibody concentration
Number of Seroprotected Subjects Against Anti-Hepatitis B (Anti-HBs) Antigens	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	A seroprotected subject was a subject whose antibody concentration was greater than or equal to the level defining clinical protection of 10 milli-international units per millilitre (mIU/mL).
Number of Seroprotected Subjects Against Anti-HBs Antigens	Before (PRE) booaster vaccination (subjects enrolled after protocol amendment 2)	A seroprotected subject was a subject whose antibody concentration was greater than or equal to the level defining clinical protection of 10 milli-international units per millilitre (mIU/mL).
Concentrations for Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibodies	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.15 µg /mL.
Number of Seropositive Subjects for Anti-PNE Serotypes	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	A seropositive subject was defined as a vaccinated subject who had anti- pneumococcal antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL). The anti-PNE serotypes assessed were 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Number of Subjects Reporting Any Solicited Local Symptom	During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled after protocol amendment 2)	Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade.
Anti-Hepatitis B (Anti-HBs) Antibody Concentrations	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2))	Concentrations were expressed as geometric mean concentrations (GMCs). Seroprotection cut-off assay was 10 mIU/mL.
Anti-HBs Antibody Concentrations	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). Seroprotection cut-off assay was 10 mIU/mL.
Concentrations for Anti-poliovirus Types 1, 2 and 3	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean titers (GMTs). The seroprotection cut-off of the assay was 8.
Number of Seroprotected Subjects Against Anti-Poliovirus Type 1, 2 and 3	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)	A seroprotected subject was a subject whose antibody titre was greater than or equal to the level defining clinical protection of 8.
Concentrations for Anti-PRP Antibodies	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.15 µg /mL.
Number of Seroprotected Subjects for Anti-polyribosyl-ribitol Phosphate (Anti-PRP)	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL).
Concentrations for Anti-pneumococcal (Anti-PNE) Antibodies	1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 0.15 µg /mL. The anti-PNE serotypes assessed were 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Number of Subjects Reporting Any Solicited General Symptom	During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled after protocol amendment 2)	Solicited local symptoms assessed were drowsiness, irritability/fussiness, loss of appetite and fever \[axillary temperature above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of any local symptom regardless of intensity grade.
Concentrations for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies	Before (PRE) and 1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.
Concentrations for Anti-D and Anti-T Antibodies	Before (PRE) 1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Concentrations for Anti-PT, Anti-FHA and Anti-PRN	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). Seropositivity cut-off assay was 5 EL.U/mL.
Anti-Hepatitis B (Anti-HBs) Antibody Concentration	Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). Seroprotection cut-off assay was 10 mIU/mL.
Concentration for Anti-poliovirus Type 1, 2 and 3	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean titers (GMTs). The seroprotection cut-off of the assay was 8.
Number of Seroprotected Subjects for Anti-PRP	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)	A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL).
Concentrations for Anti-PNE Antibodies	1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)	Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 0.15 µg /mL. The anti-PNE serotypes assessed were 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Concentrations for Anti-polyribosyl-ribitol Phosphate Antibodies	Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.15 µg /mL.
Number of Subjects With Booster Response to Anti-pertussis Antigens	1 month poste booster vaccination (POST) (subjects enrolled after protocol amendment 2)	Booster response defined as : - For initially seronegative subjects, antibody concentration ≥ 5 EL.U/mL one month after booster vaccination - For initially seropositive subjects, antibody concentration at Post-booster ≥ 2 fold the pre-vaccination antibody concentration
Number of Subjects Reporting Any Solicited Local Symptoms	During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled before protocol amendment 2)	Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade.
Number of Subjects Reporting Any Solicited General Symptoms	During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled before protocol amendment 2)	Solicited local symptoms assessed were drowsiness, irritability/fussiness, loss of appetite and fever \[axillary temperature above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of any local symptom regardless of intensity grade.
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)	Within the 31-day (Days 0-30) follow up period after vaccination. (subjects enrolled before protocol amendment 2)	An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination.
Number of Subjects Reporting Any Unsolicited AEs	Within the 31-day (Days 0-30) follow up period after vaccination. (subjects enrolled after protocol amendment 2)	An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination.
Number of Subjects Reporting Any Serious Adverse Events (SAEs)	During the entire study period (Days 0-30). (subjects enrolled before protocol amendment 2)	SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Any SAE = any SAE regardless of assessment of relationship to study vaccination.
Number of Subjects Reporting Any SAEs	During the entire study period (Days 0-30). (subjects enrolled after protocol amendment 2)	SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Any SAE = any SAE regardless of assessment of relationship to study vaccination.

Trial Locations

Locations (1)

GSK Investigational Site; 🇫🇮 Vantaa, Finland